BioNTech SE ADR (NASDAQ:BNTX) price on Friday, March 21, fall -0.88% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $95.38.
A look at the stock’s price movement, the close in the last trading session was $96.23, moving within a range at $94.5 and $96.045. The beta value (5-Year monthly) was 0.308. Turning to its 52-week performance, $131.49 and $76.53 were the 52-week high and 52-week low respectively. Overall, BNTX moved -19.09% over the past month.
BioNTech SE ADR’s market cap currently stands at around $22.89 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-09.
Analysts have a consensus estimate of 159.6M for the company’s revenue for the quarter, with a low and high estimate of 89M and 266.4M respectively. The average forecast suggests down to a -14.92% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 2.12B, representing a -23.03% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that BNTX is a 50% Sell. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
13 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 9 recommend BNTX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 2 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
BNTX’s current price about -9.63% and -15.81% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 34.44, while 7-day volatility ratio is 2.77% and 4.07% in the 30-day chart. Further, BioNTech SE ADR (BNTX) has a beta value of 1.05, and an average true range (ATR) of 4.36. Analysts have given the company’s stock an average 52-week price target of $126, forecast between a low of $121 and high of $145. Looking at the price targets, the low is -26.86% off current price level while to achieve the yearly target high, price needs to move -52.02%. Nonetheless, investors will most likely welcome a -32.1% jump to $126 which is the analysts’ median price.
If we refocus on BioNTech SE ADR (NASDAQ:BNTX), historical trading data shows that trading volumes averaged 0.86 over the past 10 days and 748.25K over the past 3 months. The company’s latest data on shares outstanding shows there are 239.97 million shares.
The 1.56% of BioNTech SE ADR’s shares are in the hands of company insiders while institutional holders own 20.66% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.82 million on 2025-02-28, giving us a short ratio of 3.62. The data shows that as of 2025-02-28 short interest in BioNTech SE ADR (BNTX) stood at 306.0 of shares outstanding, with shares short rising to 2.74 million registered in 2025-01-31. Current price change has pushed the stock -16.30% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the BNTX stock continues to rise going into the next quarter.
